Study investigators expect that J&J's combo drug can extend overall survival by at least a year over the current standard of ...

Halozyme (HALO) says the European Commission OK'd an injectable version of J&J's (JNJ) cancer drug, Rybrevant for certain ...

Subcutaneous amivantamab is co-formulated Halozyme's ENHANZE ® drug delivery technology. "We are delighted to announce the European approval of the subcutaneous formulation of amivantamab ...

A key step for J&J will be securing FDA approval for a subcutaneous version of Rybrevant, which would significantly reduce administration time. However, the company’s initial attempt was ...

Halozyme Therapeutics (HALO) announced that Janssen-Cilag International NV, a Johnson & Johnson (JNJ) company, has received European ...

Nevertheless, it is a setback for J&J. The current intravenous formulation of Rybrevant has picked up four FDA approvals in previously untreated and relapsed/refractory EGFR-mutated NSCLC - as a ...

Daiichi Sankyo-partnered anti-HER2 drug Enhertu (trastuzumab deruxtecan) has been cleared by the European Commission for use ...

The latest data from Johnson and Johnson's Rybrevant and Lazcluze lung cancer combo was better than standard of care Tagrisso on overall survival. But analysts say the next step is getting a ...

Subcutaneous Rybrevant is co-formulated with Halozyme's ENHANZE drug delivery technology. The EC approval is supported by positive results from the Phase 3 PALOMA-3 study. The views and opinions ...

Johnson & Johnson's MARIPOSA study shows Rybrevant plus Lazcluze significantly extends overall survival in first-line EGFR-mutated NSCLC over osimertinib.